Skip to content

Effect of psychiatric medicine on the levels of blood components in major psychiatric disorders over time

Effect of medication on the levels of various novel inflammatory biomarkers in patients of major psychiatric disorders - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/101126
Enrollment
80
Registered
2026-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F40-F48- Anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders Health Condition 2: F01-F99- Mental, Behavioral and Neurodevelopmental disorders Health Condition 3: F30-F39- Mood [affective] disorders Health Condition 4: F20-F29- Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders

Interventions

Intervention1: Nil: Nil

Sponsors

Vaishnav Sethumadhavan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder) as per ICD-11 or DSM-5 criteria by a consultant psychiatrist Drug-na ve or free of psychiatric medication for at least 12 weeks before baseline sample collection. Willingness and ability to comply with study procedures and follow-up schedule and have provided written informed consent.

Exclusion criteria

Exclusion criteria: Presence of acute or chronic inflammatory, infectious, or autoimmune diseases (e.g., TB, SLE, rheumatoid arthritis). Use of anti-inflammatory medications (e.g., NSAIDs, corticosteroids) within the past 2 weeks. Pregnant or lactating women. History of immunosuppressive therapy in the past 6 months Refusal to provide blood samples or inability to complete follow-up assessments

Design outcomes

Primary

MeasureTime frame
To analyze the pattern and trajectory of inflammatory biomarker like NLR,LMR,PLR,SII,SIRI and AISI at baseline and over the 8-week treatment period.Timepoint: Baseline 2 weeks on treatment 4 weeks on treatment 6 weeks on treatment 8 weeks on treatment

Secondary

MeasureTime frame
To evaluate the association between changes in biomarker levels and changes in clinical symptom severity over time. Timepoint: Baseline 2 weeks 4 weeks 6 weeks 8 weeks

Countries

India

Contacts

Public ContactVaishnav Sethumadhavan

Vinayaka Missions Kirupananda Variyar Medical College Hospital

pradeep.chandrasekaran87@gmail.com88723 77927

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026